Uncategorized

Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease

by Business Wire • 2018/01/05 • 0 Comments

WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals today announced topline results from its two Phase 3 clinical trials in patients with dry eye disease.

Full Story →

← Kala Pharmaceuticals Announces New Drug Application for INVELTYSTM (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration

Shingles and Shingles Vaccine: An Update →

Post navigation